Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Rating of “Moderate Buy” by Analysts

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has received a consensus rating of “Moderate Buy” from the fourteen brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, nine have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $17.25.

AMLX has been the topic of several research analyst reports. Citigroup raised their price objective on Amylyx Pharmaceuticals from $12.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen downgraded shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. HC Wainwright raised their target price on shares of Amylyx Pharmaceuticals from $16.00 to $20.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Finally, Robert W. Baird lifted their target price on Amylyx Pharmaceuticals from $10.00 to $19.00 and gave the company an “outperform” rating in a research note on Thursday, October 16th.

Amylyx Pharmaceuticals Stock Down 0.1%

Shares of Amylyx Pharmaceuticals stock opened at $11.38 on Wednesday. The business has a 50-day moving average price of $13.13 and a 200 day moving average price of $11.25. Amylyx Pharmaceuticals has a fifty-two week low of $2.60 and a fifty-two week high of $16.96. The firm has a market cap of $1.25 billion, a P/E ratio of -6.32 and a beta of -0.31.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its earnings results on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06. As a group, equities research analysts anticipate that Amylyx Pharmaceuticals will post -2.2 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Karen Firestone purchased 8,100 shares of the stock in a transaction dated Tuesday, December 23rd. The stock was acquired at an average price of $12.45 per share, for a total transaction of $100,845.00. Following the completion of the transaction, the director owned 63,100 shares of the company’s stock, valued at approximately $785,595. The trade was a 14.73% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Camille L. Bedrosian sold 6,580 shares of Amylyx Pharmaceuticals stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $14.35, for a total transaction of $94,423.00. Following the completion of the sale, the insider owned 175,756 shares in the company, valued at approximately $2,522,098.60. This represents a 3.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 12.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Maven Securities LTD bought a new stake in shares of Amylyx Pharmaceuticals during the third quarter valued at approximately $951,000. TCG Crossover Management LLC increased its position in Amylyx Pharmaceuticals by 5.0% in the 3rd quarter. TCG Crossover Management LLC now owns 6,243,812 shares of the company’s stock valued at $84,853,000 after acquiring an additional 300,000 shares during the period. Dark Forest Capital Management LP acquired a new stake in Amylyx Pharmaceuticals in the 3rd quarter valued at approximately $1,180,000. Verition Fund Management LLC bought a new stake in Amylyx Pharmaceuticals during the 3rd quarter valued at $868,000. Finally, Paradigm Biocapital Advisors LP acquired a new position in Amylyx Pharmaceuticals during the 3rd quarter worth $25,821,000. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.